Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer with 18F-FDG PET/CT
Authors:
- 29 March 2019
- journal article
- research article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 60 (11) , 1524-1530
Abstract
The aim of this prospective investigation was to assess the association of 18F-FDG PET/CT with time to hormonal treatment failure (THTF) in men with metastatic castrate-sensitive prostate cancer (mCSPC). Methods: 76 men with mCSPC recruited from 2005-2011 underwent 18F-FDG PET/CT and were followed prospectively for THTF, defined as treatment change to chemotherapy or death. Patients who had not switched to chemotherapy were censored at the last follow-up date (median of 36 months, range 12-108 months). Cox regression analyses were performed to examine the association between PET/CT measurements: sum of SUVmax, maximum of SUVmax, and average of SUVmax of up to 10 of the most active lesions and THTF. Survival probabilities were based on the Kaplan-Meier method. Results: 43 patients had hormonal treatment failure and 8 died without documented treatment failure. Median THTF was 26.5 months (95% CI: 15.5-46.6 months). The THTF-free probability at 5 years was 35%+/-6%. In univariate analysis, all PET parameters including number of lesions were statistically significant for THTF. In a reduced multivariate model accounting for clinical variables, only sum of SUVmax (HR 1.01, 95% CI: 1.002-1.03, P = 0.024) and number of lesions (HR 1.18, 95% CI: 1.08-1.29, pmax was grouped into quartile ranges, there was significantly worse survival probability for patients in the 4th quartile range compared to the 1st, with a univariate hazard ratio of 6.2 (95% CI: 2.8-13.6, pConclusion: Sum of SUVmax and number of lesions derived from 18F-FDG PET/CT provides independent prognostic information on THTF in men with mCSPC.Keywords
This publication has 35 references indexed in Scilit:
- Baseline 18F-FDG PET/CT Parameters as Imaging Biomarkers of Overall Survival in Castrate-Resistant Metastatic Prostate CancerJournal of Nuclear Medicine, 2013
- Molecular Imaging of Prostate Cancer: PET RadiotracersAmerican Journal of Roentgenology, 2012
- Modern Detection of Prostate Cancer's Bone Metastasis: Is the Bone Scan Era Over?Advances in Urology, 2011
- Characterising the castration-resistant prostate cancer population: a systematic reviewInternational Journal Of Clinical Practice, 2011
- Prognostic Value of Baseline [18F] Fluorodeoxyglucose Positron Emission Tomography and 99mTc-MDP Bone Scan in Progressing Metastatic Prostate CancerClinical Cancer Research, 2010
- Castration-Dependent Pharmacokinetics of Docetaxel in Patients With Prostate CancerJournal of Clinical Oncology, 2010
- Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PETNature Reviews Urology, 2009
- FDG PET in Prostate CancerPET Clinics, 2009
- Metastatic Carcinoma of the Prostate: Identifying Prognostic Groups Using Recursive PartitioningJournal of Urology, 2003
- Bilateral Orchiectomy with or without Flutamide for Metastatic Prostate CancerNew England Journal of Medicine, 1998